Breaking News Instant updates and real-time market news.

RAD

Rite Aid

$8.47

-0.14 (-1.63%)

07:03
12/22/16
12/22
07:03
12/22/16
07:03

Rite Aid reports Q3 adjusted EPS 2c, consensus 4c

Reports Q3 revenue $8.1B, consensus $8.23B. Retail Pharmacy Segment revenues were $6.5B and decreased 3.1% compared to the prior year period primarily as a result of a decrease in same store sales. Revenues in the company's Pharmacy Services Segment were $1.6B and increased 9.7% compared to the prior year period. Same store sales for the quarter decreased 3.4% over the prior year, consisting of a 4.7% decrease in pharmacy sales and a 0.4% decrease in front-end sales. Pharmacy sales included an approximate 182 basis point negative impact from new generic introductions.

RAD Rite Aid
$8.47

-0.14 (-1.63%)

11/08/16
LEER
11/08/16
NO CHANGE
Target $90
LEER
Outperform
Walgreens Boots Alliance price target lowered to $90 from $95 at Leerink
Leerink analyst David Larsen lowered his price target for Walgreens Boots Alliance (WBA) to $90 from $95, noting that he is negatively surprised that Rite Aid (RAD) is expected to add just 5c-12c to 2017 EPS, and also somewhat concerned that 2017 is expected to be a back-half loaded year. Furthermore, the analyst is slightly more cautious on Rite Aid deal's odds, but sees about 65% chance of it closing. Larsen reiterates an Outperform rating on Walgreens Boots Alliance's shares.
11/09/16
DBAB
11/09/16
NO CHANGE
Target $88
DBAB
Buy
Deutsche still expects Walgreens, Rite Aid deal to close
After speaking to private equity executives, Deutsche Bank analyst George Hill continues to expect Walgreens Boots Alliance's acquisition of Rite Aid (RAD) to be completed. The analyst says the conversations support his belief that most of the divested stores will go to strategic buyers, which he thinks is the FTC preference. Hill has a Buy rating on Walgreens with an $88 price target.
11/15/16
LEER
11/15/16
NO CHANGE
Target $85
LEER
Outperform
CVS Health price target lowered to $85 from $105 at Leerink
Leerink analyst David Larsen lowered his price target for CVS Health (CVS) to $85 from $105 as he is incrementally more cautious on the company. Conversely, the analyst is incrementally more positive on Walgreens Boots Alliance (WBA) and believes its deal with Rite Aid (RAD) deal is more likely to go through with Trump as President. Nonetheless, Larsen believes that 2017 is largely a re-set year for CVS Health, and expects the business to return to more robust growth in 2018 and beyond. He reiterates an Outperform rating on CVS Health's shares.
12/20/16
EVER
12/20/16
NO CHANGE
EVER
Cardinal Health likely to benefit from Fred's asset acquisition, says Evercore ISI
Evercore ISI analyst Ross Muken said Cardinal Health (CAH) is likely to benefit from Fred's (FRED) acquisition of 865 stores from Walgreens Boots (WAG)/Rite Aid (RAD) as it is Fred's current distributor.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.